bluebird bio Stock Forecast, Price & News

+0.20 (+0.61 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume523,084 shs
Average Volume1.81 million shs
Market Capitalization$2.22 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

bluebird bio logo

About bluebird bio

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent Ã-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.89 out of 5 stars

Medical Sector

134th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

20th out of 198 stocks

Analyst Opinion: 4.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio
or view top-rated stocks.

What stocks does MarketBeat like better than bluebird bio?

Wall Street analysts have given bluebird bio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but bluebird bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting bluebird bio?

bluebird bio saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 5,110,000 shares, a decline of 13.4% from the May 13th total of 5,900,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 3.8 days. Approximately 7.7% of the shares of the company are sold short.
View bluebird bio's Short Interest

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for bluebird bio

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, May, 4th. The biotechnology company reported ($3.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($3.02) by $0.05. The biotechnology company had revenue of $12.79 million for the quarter, compared to the consensus estimate of $10.71 million. bluebird bio had a negative net margin of 257.34% and a negative trailing twelve-month return on equity of 43.18%.
View bluebird bio's earnings history

How has bluebird bio's stock price been impacted by Coronavirus?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLUE shares have decreased by 46.4% and is now trading at $32.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BLUE?

18 analysts have issued 12 month price objectives for bluebird bio's stock. Their forecasts range from $27.00 to $93.00. On average, they anticipate bluebird bio's share price to reach $60.53 in the next year. This suggests a possible upside of 83.5% from the stock's current price.
View analysts' price targets for bluebird bio
or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 48, Pay $841.95k)
  • Mr. William D. Baird III, CFO and Principal Financial & Accounting Officer (Age 49, Pay $718.61k)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 50, Pay $627.91k)
  • Dr. David M. Davidson, Consultant (Age 57, Pay $668.07k)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 48)
  • Dr. Derek Adams Ph.D., Chief Technology & Manufacturing Officer
  • Ms. Ingrid Goldberg, VP of Investor Relations
  • Ms. Elizabeth Pingpank, Director of Corp. Communications
  • Ms. Kathleen A. Wilkinson, Chief People Officer (Age 49)
  • Mr. Andrew Obenshain, Pres of Severe Genetic Diseases (Age 47)

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Nick Leschly has an approval rating of 74% among bluebird bio's employees.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.91%), Royal Bank of Canada (5.40%), Armistice Capital LLC (2.91%), Suvretta Capital Management LLC (1.93%), Victory Capital Management Inc. (1.67%) and JPMorgan Chase & Co. (1.62%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III.
View institutional ownership trends for bluebird bio

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Fiera Capital Corp, Victory Capital Management Inc., Morgan Stanley, Man Group plc, Nuveen Asset Management LLC, New York State Common Retirement Fund, and Price T Rowe Associates Inc. MD. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, Andrew Obenshain, David Davidson, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, and William D Baird III.
View insider buying and selling activity for bluebird bio
or view top insider-selling stocks.

Which major investors are buying bluebird bio stock?

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Suvretta Capital Management LLC, Sessa Capital IM L.P., Voloridge Investment Management LLC, Deerfield Management Company L.P. Series C, JPMorgan Chase & Co., Royal Bank of Canada, and Ameriprise Financial Inc..
View insider buying and selling activity for bluebird bio
or or view top insider-buying stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $32.98.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $2.22 billion and generates $250.73 million in revenue each year. The biotechnology company earns $-618,700,000.00 in net income (profit) each year or ($9.95) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 1,201 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is

Where are bluebird bio's headquarters?

bluebird bio is headquartered at 60 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.